ESTRO 35 2016 S23 ______________________________________________________________________________________________________ ductal carcinomas in situ. Axillary lymph node involvement was seen in 34.3%. Most of the tumors were estrogen positive (68.75%) and progesterone positive (65.6%). A systemic therapy was given in 81.25% of the patients. After second breast conserving therapy or no surgery re-RT was given to the involved quadrant using external-beam ports (electrons or photons) with doses of 50-60Gy in 2Gy per fraction. The median age at local relapse was 65.8 years. A second breast conserving therapy was performed in 90.7% of the women, 9.3% had no surgery and were re-irradiated to a dose of 60Gy. A systemic therapy was given in 84.3%.Survival and local control were calculated by the Kaplan-Meier actuarial method.
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Institute Verbeeten, Radiation Oncology, Tilburg, The Netherlands Purpose or Objective: Cancer en cuirasse is a severe locoregional manifestation of breast cancer, usually occurring after a number of treatment failures. Treatment options are limited. One hundred and sixty-nine patients were treated with re-irradiation and hyperthermia (reRT+HT) from 1982 till 2006. Response and toxicity rates as well as the locoregional progression free interval were determined to assess the palliative value of this treatment.
Material and Methods:
All patients had received extensive previous treatments, including surgery, irradiation (median dose 50Gy with or without boost) and systemic treatments.. Seventy-five percent of patients had 1-7 previous locoregional recurrence episodes; 68% were treated with systemic therapies and 27% underwent salvage surgery. At start of re-RT+HT the tumor area comprised > 3/4 ipsilateral chest wall in 54% of patients. Fifty-two percent had areas of ulcerating tumor. Distant metastases were present in 45% of patients. reRT consisted typically of 8x4Gy, twice a week or 12x3Gy, four times a week. Superficial hyperthermia was applied once or twice a week using 434MHz Contact Flexible Microstrip Applicators (CMFA), heating the tumor area to 41-43˚C for one hour.
Results:
The treatment was well tolerated; 154 patients completed treatment, only 15 patients did not, due to disease progression in 12, toxicity in 2 and refusal in 1 patient. Overall clinical response rate was 72% (30% CR; 42% PR), while only 6% showed PD. Median follow-up time was 7 months. The 1-year progression-free-interval was 24% with a 1-year survival rate of 36%. Acute ≥ grade 3 toxicity occurred in 33% of patients and consisted mostly of ulceration and dermatitis. The occurrence of radiation ulcera was significantly related to the presence of ulcerating tumor before the start of the reRT-HT (P=0.004, HR = 4.4).
Conclusion:
The combination of re-irradiation and hyperthermia is well tolerated and results in high response rates despite extensive disease and resistance to previous treatments. ReRT+HT is a worthwhile palliative treatment option for this patient group who suffer from extensive locoregional tumor growth and have a very poor prognosis. Purpose or Objective: Stereotactic radiotherapy (SRT) of brain metastases results in regression of most treated metastases, but subsequent lesion growth may occur and is caused by either tumor progression or pseudo-progression, which is probably a radiation effect on surrounding normal brain tissue. It is unknown if active treatment is indicated in symptomatic patients, or if it is better to wait for spontaneous recovery. The purpose of this study is to describe the clinical course of brain metastasis patients developing pseudo-progression after SRT to improve clinical decision-making.
Material and Methods:
Follow-up MRI scans of all patients who received SRT of brain metastases from 2009 through 2012 were reviewed for post SRT lesion growth. Depending on the volume of the metastasis, the patients had received one fraction of 21Gy, 18Gy, or 15Gy, or three fractions of 8Gy or 8.5Gy. The GTV-PTV margin was 2mm. Pseudo-progression was considered to be the cause of this lesion growth if a histological diagnosis of necrosis had become available, if the lesion had shown subsequent regression or if two neuroradiologists agreed upon this diagnosis based on a review of the follow-up perfusion MRI scans. The clinical course of the patients with these pseudo-progressive lesions was retrospectively studied.
Results:
In a total of 237 treated patients we identified 37 patients with 50 pseudo-progressive lesions. The median follow-up of all patients still alive was 40.7 months. The main clinical symptoms that were attributed to this lesion growth were neurologic deficits, headache and seizures in 19 (51%), 3 (8%) and 4 (11%) patients respectively (unknown in one). Ten patients (27%) had no symptoms attributed to the lesion growth and remained asymptomatic afterwards. Of the 19 patients with neurologic deficits one improved after spontaneous regression of the lesion, one improved after surgery and 17 did not improve. Two out of the four patients with seizures improved with ant-epileptic drugs (AED's), one improved after surgery and one did not improve. Only one of the three patients with headache improved with steroids. Spontaneous regression of an initially pseudo-progressive lesion was observed in 18 patients. Twelve of these 18 patients had symptomatic pseudo-progression, but only one of these 12 patients experienced neurologic improvement without treatment. In 6 patients their deaths were related to the pseudo-progressive lesion.
Conclusion:
Patients with an asymptomatic pseudoprogressive lesion frequently remain asymptomatic. Patients with a symptomatic pseudo-progressive lesion only rarely recover spontaneously. Active treatment, such as surgery, should be considered for these patients. Therefore, Material and Methods: Between 2009 and 2015, 571 intermediate and high risk prostate cancer patients were enrolled in the FLAME trial, a phase 3, single blind, multicenter randomized controlled trial (NCT01168479). The control arm (287 patients) received a dose of 77Gy to the entire prostate gland in 35 fractions. The experimental arm (284 patients) received the same dose, but with an integrated boost up to 95Gy to the multi-parametric MRIbased intraprostatic lesion. For this study, the urethra was delineated retrospectively on T2 weighted MRI, using a circle shape with a diameter of 3 mm, to obtain dose parameters. These dose parameters, the Genitourinary Toxicity scores(CTCAE v3.0) and the urinary symptoms scale of the EORTC QLQ-PR25, were compared for both treatment arms. The physician in attendance scored toxicity at baseline, weekly during treatment, 4 weeks after treatment and every 6 months up to 10 years. QoL was filled out 1 week before treatment and the next questionnaires were sent to the patient every 6 months up to 10 years. Mean differences between groups at 1 year of follow-up were calculated using an independent samples t-test (dosimetry and QoL), Chisquare test or Fisher's exact test (toxicity). Statistical significance was considered P<0.01.
Results:
Results after analysis of 100 patients (50 patients in each treatment arm) with a median follow-up of 22 months show for the control arm an average Dmean (mean dose to the urethra) of 77.3 ± 0.5 Gy (range 75.9-78.0 Gy), with an average Dmax (maximum dose to the urethra) of 79.6 ± 0.8 Gy (range 78.0-81.3). In the experimental arm, average Dmean was 82.0 ± 2.8 Gy (range 77.4-89.0 Gy) and average Dmax was 89.7 ± 0.6 Gy (range 80.7-97.7 Gy). For both Dmean and Dmax the difference between treatment arms was significant (p=0.000). Grade 3 GU toxicity did not occur, grade 2 GU toxicity occurred in a subset of patients, although no significant difference was found between both treatment arms for the separate GU items (table 1) . Urinary symptomsrelated QOL was not significantly different across treatment arms.
Conclusion:
Results showed a significant difference in urethral dose, but no significant differences in toxicity or quality of life when comparing both treatment arms of the FLAME trial.
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Cardiotoxicity and cardiac substructure dosimetry in doseescalated lung radiotherapy S. Vivekanandan Guy's and St Thomas' Hospital, Oncology, London, United Kingdom Purpose or Objective: Radiotherapy of lung cancer delivers quite high doses of radiation to the heart. We explored associations between overall survival (OS) and radiation dose to heart and its substructures and electrocardiographic (ECG) changes.
Material and Methods:
We analysed data from 79 patients in IDEAL CRT, a phase I/II trial of isotoxic radiotherapy (RT) dose escalation trial, sponsored by University College London (C13530/A10424). Mean and maximum prescribed doses were 69 and 75.6Gy calculated as 2Gy fractionation equivalents (EQD2, α/β=10Gy). Whole heart, left ventricle (LV), right ventricle (RV), right atrium (RA), left atrium (LA) and AV node (AVN) were outlined on RT planning scans and differential dose volume histograms (DVHs) extracted, converting physical DVHs to EQD2s (α/β=3). Patient-topatient DVH variability was represented using a small number of Varimax-rotated principal components (PCs) explaining 95% of total variance. ECGs were analysed at baseline, 6 and 12 months (mo) after treatment, and changes in heart rate (HR) recorded, with patients dichotomised according to presence or absence of 'any ECG rhythm change' (conduction abnormalities or ischaemia). OS was modelled using Cox regression from the start of treatment. Univariate analysis (UVA) and multivariate analysis (MVA) of clinical factors included 'any rhythm ECG change' at 6 and 12 months, change in HR at 6 or 12 months, planning target volume (PTV), and prescribed dose (PD). MVA of whole heart dosimetric factors included all 7 Heart PCs, PTV, and PD. MVA of heart substructures included heart substructure PCs with p < 0.2 on UVA having similar dosimetric distributions to significant Heart PCs, PTV and PD.
